Completed PHASE3 NCT00401193

Efficacy and Safety of XP12B in Women With Menorrhagia

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study To Evaluate Efficacy and Safety of XP12B for the Treatment of Menorrhagia

Sponsor: Ferring Pharmaceuticals

Conditions Heavy Menstrual Bleeding Menorrhagia

Interventions Placebo tablets Tranexamic acid tablets

Updated 7 times since 2017 Last updated: Apr 23, 2015 Started: Nov 30, 2006 Primary completion: May 31, 2008 Completion: May 31, 2008

This PHASE3 trial investigates Heavy Menstrual Bleeding and Menorrhagia and is currently completed. Ferring Pharmaceuticals leads this study, which shows 7 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Nov 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ferring Pharmaceuticals

Data source: Ferring Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Ann Arbor, United States , Atlanta, United States , Austin, United States , Baltimore, United States , Bingham Farms, United States , Birmingham, United States , Bismarck, United States , Bloomington, United States , Boise, United States and 69 more locations